for people ages 18 years and up (full criteria)
at La Jolla, California and other locations
study started
estimated completion



This study will evaluate the safety and efficacy of Relamorelin compared to placebo in patients with diabetic gastroparesis. Patients will report daily severity scores of their diabetic gastroparesis symptoms.

Official Title

A 12-week, Randomized, Double-blind, Placebo-controlled, Phase 3 Study to Evaluate the Safety and Efficacy of Relamorelin in Patients With Diabetic Gastroparesis


Active, not recruiting due to COVID-19


Gastroparesis Diabetes Mellitus Relamorelin Relamorelin 10 μg


You can join if…

Open to people ages 18 years and up

  • Diagnosis of Type 1 or Type 2 diabetes mellitus
  • Meet the per protocol criteria of diabetic gastroparesis
  • Compliance with diary
  • Compliance with the per protocol study treatment dosing instructions

You CAN'T join if...

  • Currently receiving nutrition intravenously, by nasogastric tube, or other feeding tube
  • Actively experiencing anorexia nervosa, binge-eating, bulimia, or other eating disorder at the time of Screening (Visit 1)
  • Diagnosis of Celiac Disease, also a history of non-celiac gluten sensitivity
  • History of gastrointestinal disorders that may be similar to gastroparesis
  • Functional dyspepsia diagnosed before the diagnosis of diabetes mellitus


  • University of California San Diego
    La Jolla California 92037 United States
  • Medical Associates Research Group, Inc
    San Diego California 92123 United States
  • Clinical Applications Laboratories, Inc.
    San Diego California 92103 United States